Monoclonal antibodies harness your body's natural defenses — delivering precision protection without the limitations of traditional vaccines.
Unlike broad-spectrum approaches, mAbs are engineered to lock onto specific pathogen targets with extraordinary accuracy — neutralizing threats before they spread.
No waiting weeks for immunity to build. mAbs deliver ready-made antibodies that go to work within hours — critical for vulnerable populations and active outbreaks.
As pathogens evolve, mAbs can be redesigned in weeks — not months. This agility keeps protection current against even the fastest-mutating threats.
Scientists isolate the most effective antibodies from recovered patients or engineer them to target specific viral proteins.
These antibodies are cloned and optimized for maximum potency and duration — extending protection for months from a single dose.
Once administered, mAbs immediately bind to the virus, blocking it from entering cells and flagging it for immune system cleanup.
No immune activation needed. Your body receives ready-made defense that works alongside your natural immune system.
"Monoclonal antibodies represent a transformative advance — offering immediate, targeted protection to those who need it most, regardless of their immune status."— Leading Infectious Disease Researcher
Clinical trials demonstrate broad neutralizing activity across emerging strains.
New framework could accelerate access to updated antibody treatments.
Beyfortus data confirms dramatic reduction in severe RSV hospitalizations.